Cite
Antoniu SA. Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666. Expert Opin Investig Drugs. 2007;16(3):393-5doi: 10.1517/13543784.16.3.393.
Antoniu, S. A. (2007). Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666. Expert opinion on investigational drugs, 16(3), 393-5. https://doi.org/10.1517/13543784.16.3.393
Antoniu, Sabina A. "Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666." Expert opinion on investigational drugs vol. 16,3 (2007): 393-5. doi: https://doi.org/10.1517/13543784.16.3.393
Antoniu SA. Cyclophosphamide for scleroderma interstitial lung disease. Tashkin DP, Elashoff R, Clements PJ et al.: Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med. (2006) 354(25):2655-2666. Expert Opin Investig Drugs. 2007 Mar;16(3):393-5. doi: 10.1517/13543784.16.3.393. PMID: 17302533.
Copy
Download .nbib